1008 Risk-reducing surgery (RRS) in hereditary breast and ovarian cancer syndrome (HBOS): retrospective monocentric study

Introduction/Background Pathogenic variants of BRCA1 and BRCA2 result in hereditary breast-ovarian cancer syndrome (HBOS) in affected persons. RRS included risk-reducing mastectomy (RRM) and risk-reducing salpingoophorectomy (RRSO). We aimed to analyze patients with BRCA mutations in a single center experience. Methodology RRS was performed in all patients carrying BRCA1 (aged between 25–52 years) referred at N.N. Alexandrov National Cancer Centre of Belarus from 2020 till now. Fifty-three percent of the patient population had previous history of breast cancer or ovarian cancer. Results Thirty patients underwent RRS for their BRCA1/2 mutations. In our study was reveled only BRCA1 mutation. Our patients were divided in 3 groups. 1st - clinically healthy women, who carriers of BRCA 1 mutations (n=14), median age was 38 years. 9 patients underwent prophylactic subcutaneous mastectomy, 3 – prophylactic hysterectomy with bilateral salpingo-ophrectomy, 4 - only bilateral salpingo-ophrectomy. At the same time, two patients underwent both surgical prophylaxis of breast cancer and prophylaxis of ovarian cancer. In the 2nd group - 4 patients with a history of ovarian cancer - underwent prophylactic subcutaneous mastectomy, median age was 45 years. In the 3rd group - 12 patients with a previously established diagnosis of breast cancer underwent prophylactic hysterectomy with bilateral salpingo-ophrectomy, median age was 45 years. In 100% of cases we used laparoscopic minimally invasive approach. Fallopian tubes were carried out according by See-FIM protocol. There was no serous tubular intraepithelial carcinoma detected during this time. Conclusion RRS is safe and feasible in BRCA mutation carriers. It`s an important part of management prevention of HBOS. Disclosures No disclosures.